HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao reiterates a Buy rating on Marinus Pharma (NASDAQ:MRNS) and maintains a $27 price target.

April 16, 2024 | 2:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Marinus Pharma receives a reiterated Buy rating and a maintained $27 price target from HC Wainwright & Co.
The reiteration of a Buy rating and maintenance of a $27 price target by a reputable analyst firm like HC Wainwright & Co. typically signals strong analyst confidence in the company's future performance. This endorsement is likely to positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100